PT - JOURNAL ARTICLE AU - Maria Teresa Sandri AU - Elena Azzolini AU - Valter Torri AU - Sara Carloni AU - Chiara Pozzi AU - Michela Salvatici AU - Michele Tedeschi AU - Massimo Castoldi AU - Alberto Mantovani AU - Maria Rescigno TI - SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy AID - 10.1101/2020.05.24.20111245 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.24.20111245 4099 - http://medrxiv.org/content/early/2020/12/02/2020.05.24.20111245.short 4100 - http://medrxiv.org/content/early/2020/12/02/2020.05.24.20111245.full AB - Lombardy is the Italian region most affected by COVID-19. We tested the presence of plasma anti-SARS-CoV-2 IgG antibodies in 3985 employees across 7 healthcare facilities in areas of Lombardy with different exposure to the SARS-CoV-2 epidemic. Subjects filled a questionnaire to self-report on COVID-19 symptoms, co-morbidities, smoking, regular or smart-working, and the exposure to COVID-infected individuals. We show that the number of individuals exposed to the virus depended on the geographical location of the facility, ranging between 3 and 43%, consistent with the spatial variation of COVID-19 incidence in Lombardy, and correlated with family contacts. We observed a higher prevalence of females than males positive for IgG, however the level of antibodies was similar, suggesting a comparable magnitude of the response. IgG positivity among smokers was lower (7.4% vs 13.5%) although without difference in IgG plasma levels. We observed 11.9% of IgG positive asymptomatic individuals and another 23.1% with one or two symptoms. Interestingly, among the IgG positive population, 81.2% of subjects with anosmia/dysgeusia and fever were SARS-CoV-2 infected, indicating that these symptoms are strongly associated to COVID-19. The plasma level of IgG inversely correlated with anti-pneumococcal vaccination.In conclusion, the frequency of IgG positivity and SARS-CoV-2 infection is dependent on the geographical exposure to the virus and primarily to family rather than hospital exposure.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04387929Funding StatementThe study was funded by the Italian Ministry of Health (Ricerca Corrente)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Istituto clinico Humanitas and Humanitas Gavazzeni Ethical committees approved the protocol.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request